2-[3-(1H-1,3-benzodiazol-1-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione | 340179-88-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-[3-(1H-1,3-benzodiazol-1-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione
• 英文别名: 2-[3-(1H-benzimidazol-1-yl)propyl]-1H-isoindole-1,3(2h)-dione；2-[3-(benzimidazol-1-yl)propyl]isoindole-1,3-dione
• CAS: 340179-88-6
• 化学式: C₁₈H₁₅N₃O₂
• 分子量: 305.336
• InChiKey: GJCWPWXZORPNSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  55.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  苯并咪唑 、 N-(3-溴丙基)苯二胺 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[3-(1H-1,3-benzodiazol-1-yl)propyl]-2,3-dihydro-1H-isoindole-1,3-dione
  参考文献：
  名称：

  Synthesis and Evaluation of Novel N-Substituted-6-methoxynaphthalene-2-Carboxamides as Potential Chemosensitizing Agents for Cancer

  摘要：

  合成了一类新型分子，结构为 N-[3-(异芳基)丙基]-6-甲氧基萘-2-羧酰胺 8—13，通过将 6-甲氧基-2-萘酰氯 1 与 3-(异芳基)丙胺 2—7 缩合而成。化合物 8—12 在体外进行了评估，使用 SRB 法检测 P388 小鼠淋巴细胞白血病细胞系 (P388) 的细胞毒性，并使用 MTT 法检测耐阿霉素的 P388 小鼠淋巴细胞白血病细胞系 (P388/ADR) 的耐药逆转活性。化合物 8—12 在 20 μg/ml 较低剂量下无毒，并有效逆转阿霉素耐药。然而，在较高剂量 (40, 80 μg/ml) 下显示出显著的细胞毒性，因此在这些浓度下未确定逆转效能。

  DOI：

  10.1248/cpb.56.894

文献信息

• NOVEL GENES RELATED TO GLUTAMINYL CYCLASE
  申请人：Schilling Stephan

  公开号：US20080249083A1

  公开（公告）日：2008-10-09

  Novel glutaminyl-peptide cyclotransferase-like proteins (QPCTLs), which are isoenzymes of glutaminyl cyclase (QC, EC 2.3.2.5), and to isolated nucleic acids coding for these isoenzymes, all of which are useful for the discovery of new therapeutic agents, for measuring cyclase activity, and for determining the inhibitory activity of compounds against these glutaminyl cyclase isoenzymes.

  小说谷氨酰肽环转移酶样蛋白（QPCTLs），它们是谷氨酰环化酶（QC，EC 2.3.2.5）的同工酶，以及编码这些同工酶的分离核酸，所有这些对于发现新的治疗药物、测量环化酶活性以及确定化合物对这些谷氨酰环化酶同工酶的抑制活性都是有用的。
• New use of glutaminyl cyclase inhibitors
  申请人：Probiodrug AG

  公开号：EP2481408A2

  公开（公告）日：2012-08-01

  The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Further, the invention relates to a respective diagnostic method, assay and kit.

  本发明总体上涉及谷氨酰胺肽环转酶的抑制剂，以及将其用于治疗和/或预防选 自以下一组炎症性疾病的疾病或紊乱 a. 神经退行性疾病，例如轻度认知障碍（MCI）、阿尔茨海默病、唐氏综合征的神经退行性疾病、家族性英国痴呆症、家族性丹麦痴呆症、多发性硬化症、 b. 慢性和急性炎症，如类风湿性关节炎、动脉粥样硬化、血管再狭窄、胰腺炎、 c. 纤维化，如肺纤维化、肝纤维化、肾纤维化、 d. 癌症，如癌症/血管内皮瘤增生、胃癌、 e. 代谢性疾病，如高血压、 f. 其他炎症性疾病，如神经性疼痛、移植物排斥/移植物失败/移植物血管病变、艾滋病病毒感染/艾滋病、妊娠中毒症、结节性硬化症。 此外，本发明还涉及一种相应的诊断方法、检测方法和试剂盒。
• USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES
  申请人：Hoffmann Torsten

  公开号：US20070191366A1

  公开（公告）日：2007-08-16

  The present invention provides novel physiological substrates of mammalian glutaminyl cyclase (QC, EC 2.3.2.5), new effectors of QC, methods for screening for such effectors, and the use of such effectors and pharmaceutical compositions comprising such effectors for the treatment of conditions that can be treated by modulation of QC-activity. Preferred compositions additionally comprise inhibitors of DP IV or DP IV-like enzymes for the treatment or alleviation of conditions that can be treated by modulation of QC- and DP IV-activity.
• Novel Inhibitors of Glutaminyl Cyclase
  申请人：Schilling Stephan

  公开号：US20090018087A1

  公开（公告）日：2009-01-15

  The present invention relates to novel inhibitors of glutaminyl cyclase and combinations thereof for the treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia.
• USE OF GLUTAMINYL CYCLASE INHIBITORS
  申请人：Schilling Stephan

  公开号：US20090068699A1

  公开（公告）日：2009-03-12

  An inhibitor of a glutaminyl peptide cyclotransferase, and use thereof for the treatment and/or prevention of a disease or disorder selected from the group consisting of inflammatory diseases selected from a. neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, multiple sclerosis, b. chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis, c. fibrosis, e.g. lung fibrosis, liver fibrosis, renal fibrosis, d. cancer, e.g. cancer/hemangioendothelioma proliferation, gastric carcinomas, e. metabolic diseases, e.g. hypertension, f. and other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis. Additionally disclosed are a respective diagnostic method, assay and kit.